Thromboembolic Therapies in Dogs and Cats: An Evidence-Based Approach

Veterinary Clinics of North America - Small Animal Practice

Volumn 37, Issue 3, 2007, Pages 579-609

  Lunsford, Kari V ^a   Mackin, Andrew J ^a  

^a MISSISSIPPI STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; CLOPIDOGREL; DALTEPARIN; DIPYRIDAMOLE; ENOXAPARIN; ESTROGEN DERIVATIVE; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; OMEGA 3 FATTY ACID; PLASMINOGEN ACTIVATOR; PREDNISONE; RETEPLASE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STREPTOKINASE; TENECTEPLASE; THIACETARSAMIDE; TICLOPIDINE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; WARFARIN;

ANTICOAGULANT THERAPY; AORTA THROMBOSIS; ARTERY EMBOLISM; ARTERY THROMBOSIS; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CAT DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIET SUPPLEMENTATION; DIROFILARIA IMMITIS; DOG DISEASE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; FIBRINOLYTIC THERAPY; HEPARINIZATION; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; MAINTENANCE THERAPY; META ANALYSIS; MONOTHERAPY; NONHUMAN; PHARMACODYNAMICS; REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

ANIMALS; CAT DISEASES; CATS; DOG DISEASES; DOGS; EMBOLIZATION, THERAPEUTIC; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; HEPARIN; SPECIES SPECIFICITY; THROMBOEMBOLISM; TREATMENT OUTCOME;

CANIS FAMILIARIS;

EID: 34247329821     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cvsm.2007.01.010     Document Type: Review

References (179)

1. Hirsh J., Guyatt G., Albers G.W., et al. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: evidence based guidelines. Chest 126 (2004) 172-173
2. Schünemann H.J., Munger H., Brower S., et al. Methodology for guideline development for the Seventh American College of Chest Physicians Conference of Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 174-178
3. Guyatt G., Schünemann H.J., Cook D., et al. Applying the grades of recommendation for antithrombotic and thrombolytic therapy: the Seventh ACCP Conference of Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 179-187
4. Marjerus P.W., Broze Jr. G.J., Miletich J.P., et al. Anticoagulant, thrombolytic, and antiplatelet drugs. In: Hardman J.G., Limbird L.E., Molinoff P.B., et al. (Eds). Goodman and Gilman's the pharmacologic basis of therapeutics. 9th edition (1996), McGraw-Hill, New York 1341-1359
5. Roth G.J., and Majerus P.W. The mechanism of the effect of aspirin on human platelets: I. Acetylation of a particulate fraction protein. J Clin Invest 56 (1975) 624-632
6. Majerus P.W. Arachidonate metabolism in vascular disorders. J Clin Invest 72 (1983) 1521-1525
7. 2 but not systemic prostacyclin by controlled-release aspirin. N Engl J Med 325 (1991) 1137-1141
8. McAdam B.F., Catella-Lawson F., Mardini I.A., et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 96 (1999) 272-277
9. Cipollone F., Patrignani P., Greco A., et al. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation 96 (1997) 1109-1116
10. 2 after low-dose aspirin. N Engl J Med 304 (1981) 76-79
11. Patrignani P., Filabozzi P., and Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 69 (1982) 1366-1372
12. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 330 (1994) 1287-1294
13. Quinn M.J., and Fitzgerald D.J. Ticlopidine and clopidogrel. Circulation 100 (1999) 1667-1672
14. Hogan D.F., Andrews D.A., Green H.W., et al. Antiplatelet effects and pharmacodynamics of clopidogrel in cats. J Am Vet Med Assoc 225 9 (2004) 1406-1411
15. Hirsch J., and Raschke R. Heparin and low molecular weight heparins: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 188S-203S
16. Johnson E.A., and Mulloy B. The molecular weight range of commercial heparin preparations. Carbohydr Res 51 (1976) 119-127
17. Lam L.H., Silbert J.E., and Rosenberg R.D. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 69 (1976) 570-577
18. Casu B., Oreste P., Torri G., et al. The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence. Biochem J 97 (1981) 599-609
19. Ofosu F.A., Sie P., Modi G.J., et al. The inhibition of thrombin-dependent feedback reactions is critical to the expression of anticoagulant effects of heparin. Biochem J 243 (1987) 579-588
20. Ofosu F.A., Hirsh J., Esmon C.T., et al. Unfractionated heparin inhibits thrombin-catalyzed amplification reactions of coagulation more efficiently than those catalyzed by factor Xa. Biochem J 257 (1989) 143-150
21. Beguin S., Lindhout T., and Hemker H.C. The mode of action of heparin in plasma. Thromb Haemost 60 (1988) 457-462
22. Mischke R.H., Schuttert C., and Grebe S.I. Anticoagulant effects of repeated subcutaneous injections of high doses of unfractionated heparin in healthy dogs. Am J Vet Res 62 12 (2001) 1887-1891
23. Harenberg J. Pharmacology of low molecular weight heparins. Semin Thromb Hemost 16 (1990) 12-18
24. Hirsh J., and Levine M.N. Low molecular weight heparin. Blood 79 (1992) 1-17
25. Handeland G.F., Abidgaard G.F., Holm U., et al. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol 39 (1990) 107-112
26. Abbate R., Gori A.M., Farsi A., et al. Monitoring of low-molecular-weight heparins. Am J Cardiol 82 (1998) 33L-36L
27. Levine M.N., Planes A., Hirsh J., et al. The relationship between antifactor Xa level and clinical outcome in patients receiving enoxaparin low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost 62 (1989) 940-944
28. Lunsford K, Mackin A, Langston VC, et al. Pharmacokinetics of the biological effects of subcutaneously administered enoxaparin, a low molecular weight heparin, in dogs [abstract]. Presented at the Proceedings of the American College of Veterinary Internal Medicine. 2005.
29. Mischke R., Grebe S., Jacobs C., et al. Amidolytic heparin activity and values for several hemostatic variables after repeated subcutaneous administration of high doses of a low molecular weight heparin in healthy dogs. Am J Vet Res 62 4 (2001) 595-598
30. Ansell J., Hirsch J., Poller L., et al. The pharmacology and management of vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 (2004) 204S-233S
31. Fasco M.J., Hildebrandt E.F., and Suttie J.W. Evidence that warfarin anticoagulant action involves two distinct reductase activities. J Biol Chem 257 (1982) 11210-11212
32. Nelsestuen G.L., Zytkovicz T.H., and Howard J.B. The mode of action of vitamin K: identification of γ-carboxyglutamic acid as a component of prothrombin. J Biol Chem 249 (1974) 6347-6350
33. Hirsh J., Dalen J.E., Anderson D.R., et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119 Suppl (2001) 8S-21S
34. Nelsestuen G.L. Role of gamma-carboxyglutamic acid: an unusual transition required for calcium-dependent binding of prothrombin to phospholipid. J Biol Chem 251 (1976) 5648-5656
35. Borowski M., Furie B.C., Bauminger S., et al. Prothrombin requires two sequential metal-dependent conformational transitions to bind phospholipid. J Biol Chem 261 (1986) 14969-14975
36. Kelly J.G., and O'Malley K. Clinical pharmacokinetics of oral anticoagulants. Clin Pharmacokinet 4 (1979) 1-15
37. Kirkwood T.B.L. Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thromb Haemost 49 (1983) 238-244
38. Clagett G.P., Sobel M., Jackson M.R., et al. Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 609S-626S
39. Davidian M.M., Powell A., Benenati J., et al. Initial results of reteplase in the treatment of acute lower extremity arterial occlusions. J Vasc Interv Radiol 11 (2000) 289-294
40. Ouriel K., Katzen B., Mewissen M., et al. Reteplase in the treatment of peripheral arterial and venous occlusions: a pilot study. J Vasc Interv Radiol 11 (2000) 849-854
41. Berridge D.C., Gregson R.H.S., Hopkinson B.R., et al. Randomized trial of intra-arterial recombinant tissue plasminogen activator, intravenous recombinant tissue plasminogen activator and intra-arterial streptokinase in peripheral arterial thrombolysis. Br J Surg 78 (1991) 988-995
42. Meyerovitz M.F., Goldhaber S.Z., Reagan K., et al. Recombinant tissue-type plasminogen activator versus urokinase in peripheral arterial and graft occlusions: a randomized trial. Radiology 175 (1990) 75-78
43. The STILE Investigators. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity: the STILE trial. Ann Surg 220 (1994) 251-268
44. Schweizer J., Altmann E., Florek H.J., et al. Comparison of tissue plasminogen activator and urokinase in the local infiltration thrombolysis of peripheral arterial occlusions. Eur J Radiol 23 (1996) 64-73
45. Palfrayman S.J., Booth A., and Michaels J.A. A systematic review of intra-arterial thrombolytic therapy for lower-limb ischaemia. Eur J Vasc Endovasc Surg 19 (2000) 143-157
46. Berridge D.C., Kessel D., and Robertson I. Surgery versus thrombolysis for acute limb ischaemia: initial management. Cochrane Database Syst Rev (2002) 1:CD002784
47. Nilsson L., Albrechtsson U., Jonung T., et al. Surgical treatment versus thrombolysis in acute arterial occlusion: a randomized controlled study. Eur J Vasc Surg 6 (1992) 189-193
48. Ouriel K., Shortell C.K., De Weese J.A., et al. A comparison of thrombolytic therapy with operative vascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg 19 (1994) 1021-1030
49. Weaver F.A., Comerota A.J., Youngblood M., et al. Surgical revascularization versus thrombolysis for nonembolic lower extremity native artery occlusions: results of a prospective randomized trial. J Vasc Surg 24 (1996) 513-521
50. Comerota A.J., Weaver F.A., Hosking J.D., et al. Results of prospective, randomized trial of surgery versus thrombolysis for occluded lower extremity bypass grafts. Am J Surg 172 (1996) 105-112
51. Ouriel K., Veith F.J., and Sasahara A.A. Thrombolysis or peripheral arterial surgery: phase I results. J Vasc Surg 23 (1996) 64-75
52. Ouriel K., Veith F.J., and Sasahara A.A. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. N Engl J Med 338 (1998) 1105-1111
53. Geerts W.H., Pineo G.F., Heit J.A., et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 338S-400S
54. Goldhaber S.Z., Meyerovitz M.F., Green D., et al. Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis. Am J Med 88 (1990) 235-240
55. Lensing A.W., and Hirsh J. Rationale and results of thrombolytic therapy for deep vein thrombosis. In: Bernstein E.F. (Ed). Vascular diagnosis. 4th edition (1994), Mosby, St. Louis (MO) 875-879
56. Goldhaber S.Z., Kessler C.M., Heit J., et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 2 (1988) 293-298
57. Bell W.R., Simon T.L., Stengle J.M., et al. Urokinase pulmonary embolism trial: phase 1 results; a cooperative study. JAMA 214 (1970) 2163-2172
58. Urokinase-streptokinase embolism trial: phase 2 results; a cooperative study. JAMA 229 (1974) 1606-1613
59. Moore K.E., Morris N., Dhupa N., et al. Retrospective study of streptokinase administration in 46 cats with arterial thromboembolism. Journal of Veterinary Emergency and Critical Care 10 4 (2000) 245-257
60. Anderson D.R., and Levine M.N. Thrombolytic therapy for the treatment of acute pulmonary embolism. Can Med Assoc J 146 (1992) 1317-1324
61. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 337 (1997) 657-662
62. Douketis J.D., Kearon C., Bates S., et al. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 279 (1998) 458-462
63. Hull R.D., Raskob G.E., Brant R.F., et al. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism: American-Canadian Thrombosis Study Group. Arch Intern Med 160 (2000) 229-236
64. Simonneau G., Sors H., Charbonnier B., et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 337 (1997) 663-669
65. Carson J.L., Kelley M.A., Duff A., et al. The clinical course of pulmonary embolism. N Engl J Med 326 (1992) 1240-1245
66. Sharma G.V., Burleson V.A., and Sasahara A.A. Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism. N Engl J Med 303 (1980) 842-845
67. Thompson M.F., Scott-Moncrieff J.C., and Hogan D.F. Thrombolytic therapy in dogs and cats. Journal of Veterinary Emergency and Critical Care 11 2 (2001) 111-121
68. Killingsworth C.R., Eyster G.E., Adams T., et al. Streptokinase treatment of cats with experimentally induced aortic thrombosis. Am J Vet Res 47 6 (1986) 1351-1359
69. Ramsey CC, Riepe RD, Macintire DK, et-al. Streptokinase: a practical clot buster? Proceedings, Fifth International Veterinary Emergency and Critical Care Symposium. San Antonio, TX 1996; 225-228.
70. Pion P.D. Feline aortic thromboemboli and the potential utility of thrombolytic therapy with tissue plasminogen activator. Vet Clin North Am Small Anim Pract 18 1 (1988) 79-86
71. Fox PR. Feline thromboembolism associated with cardiomyopathy. Proceedings of the Fifth Annual Veterinary Medical Forum ACVIM 1987; 714-718.
72. Ramsey C.C., Burney D.P., Macintire D.K., et al. Use of streptokinase in four dogs with thrombosis. J Am Vet Med Assoc 209 4 (1996) 780-785
73. Tater K.C., Drellich S., and Beck K. Management of femoral artery thrombosis in an immature dog. Journal of Veterinary Emergency and Critical Care 15 1 (2005) 52-59
74. Clare A.C., and Kraje B.J. Use of tissue recombinant tissue-plasminogen activator for aortic thrombolysis in a hypoproteinemic dog. J Am Vet Med Assoc 212 4 (1998) 439-443
75. Bliss S.P., Bliss S.K., and Harvey H.J. Use of recombinant tissue-plasminogen activator in a dog with chylothorax secondary to catheter-associated thrombosis of the cranial vena cava. J Am Anim Hosp Assoc 38 5 (2002) 431-435
76. Hull R., Pineo G., Mah A., et al. A randomized trial evaluating longterm low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. [abstract]. Blood 100 (2002) 148a
77. Büller H.R., Agnelli G., Hull R.D., et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 410S-428S
78. Anand S.S., Bates S., Ginsberg J.S., et al. Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times. Arch Intern Med 159 (1999) 2029-2032
79. Levine M.N., Raskob G., Landefeld S., et al. Hemorrhagic complications of anticoagulant treatment. Chest 119 Suppl (2001) 108S-121S
80. Hommes D.W., Bura A., Mazzolai L., et al. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis: a meta-analysis. Ann Intern Med 116 (1992) 279-284
81. Hull R., Delmore T., Carter C., et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 306 (1982) 189-194
82. Levine M., Gent M., Hirsh J., et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 334 (1996) 677-681
83. Koopman M.M., Prandoni P., Piovella F., et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home: the Tasman Study Group. N Engl J Med 334 (1996) 682-687
84. Merli G., Spiro T.E., Olsson C.G., et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 134 (2001) 191-202
85. Charbonnier B.A., Fiessinger J.N., Banga J.D., et al. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. Thromb Haemost 79 (1998) 897-901
86. Hull R., Pineo G.F., Mah A., et al. Safety and efficacy results for a study investigating the long-term out-of-hospital treatment of patients with proximal-vein thrombosis using subcutaneous low-molecular-weight heparin versus warfarin. Thromb Haemost 1 Suppl 1 (2001) abstract OC1647
87. Lee A.Y., Levine M.N., Baker R.I., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 (2003) 146-153
88. Lagerstedt C.I., Olsson C.G., Fagher B.O., et al. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 2 (1985) 515-518
89. Hull R., Delmore T., Genton E., et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 301 (1979) 855-858
90. Ridker P.M., Goldhaber S.Z., Danielson E., et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 348 (2003) 1425-1434
91. Kearon C., Ginsberg J.S., Kovacs M.J., et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 349 (2003) 631-639
92. Hull R., Hirsh J., Jay R., et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 307 (1982) 1676-1681
93. Crowther M.A., Ginsberg J.S., Julian J., et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 349 (2003) 1133-1138
94. Eichinger S., Minar E., Bialonczyk C., et al. D-dimer levels and risk of recurrent venous thromboembolism. J Am Med Assoc 290 (2003) 1071-1074
95. Bright J.M., Sullivan P.S., Melton S.L., et al. The effects of n-3 fatty acid supplementation on bleeding time, plasma fatty acid composition, and in vitro platelet aggregation in cats. J Vet Intern Med 8 4 (1994) 247-252
96. Boudreaux M.K., Reinhart G.A., Vaughn D.M., et al. The effects of varying dietary n-6 to n-3 fatty acid ratios on platelet reactivity, coagulation screening assays, and antithrombin III activity in dogs. J Am Anim Hosp Assoc 33 3 (1997) 235-243
97. Flanders J.A. Feline aortic thromboembolism. Compendium on Continuing Education for the Practicing Veterinarian 8 7 (1986) 473-483
98. Fox P.R. Evidence for or against efficacy of beta-blockers and aspirin for management of feline cardiomyopathies. Vet Clin N Am Small Anim Pract 21 5 (1991) 1011-1022
99. Smith S.A., Tobias A.H., Jacob K.A., et al. Arterial thromboembolism in cats: acute crisis in 127 cases (1992-2001) and long-term management with low-dose aspirin in 24 cases. J Vet Intern Med 17 1 (2003) 73-83
100. Boswood A., Lamb C.R., and White R.N. Aortic and iliac thrombosis in six dogs. J Small Anim Pract 41 3 (2000) 109-114
101. Fox P.R., Petrie J.P., and Hohenhaus A.E. Peripheral vascular disease. In: Ettinger S.J., and Feldman E.C. (Eds). Textbook of veterinary internal medicine. 6th edition (2004), WB Saunders, Philadelphia 1149-1150
102. Harpster N.K., and Baty C.J. Warfarin therapy of the cat at risk of thromboembolism. In: Bonagura J.D. (Ed). Kirk's current veterinary therapy XII (1995), WB Saunders, Philadelphia 868-873
103. Atkins CE. Therapy of feline heart disease. Presented at the 77th Annual Western Veterinary Conference. Las Vegas, NV, 2005.
104. Smith S.A., Kraft S.L., Lewis D.C., et al. Plasma pharmacokinetics of warfarin enantiomers in cats. J Vet Pharmacol Ther 23 6 (2000) 329-337
105. Smith S.A., Kraft S.L., Lewis D.C., et al. Pharmacodynamics of warfarin in cats. J Vet Pharmacol Ther 23 6 (2000) 339-344
106. Smith S.A., and Tobias A.H. Feline arterial thromboembolism: an update. Vet Clin North Am Small Anim Pract 34 5 (2004) 1245-1271
107. DeFrancesco TC, Moore RR, Atkins CE, et al. Comparison of dalteparin and warfarin in the long-term management of feline arterial thromboembolism. Presented at the ACVIM annual meeting. Charlotte, NC, 2003.
108. Smith C.E., Rozanski E.A., Freeman L.M., et al. Use of low molecular weight heparin in cats: 57 cases (1999-2003). J Am Vet Med Assoc 225 8 (2004) 1237-1241
109. Rush J.E., Freeman L.M., Fenollosa N.K., et al. Population and survival characteristics of cats with hypertrophic cardiomyopathy: 260 cases (1990-1999). J Am Vet Med Assoc 220 (2002) 202-207
110. Laste N.J., and Harpster N.K. A retrospective study of 100 cases of feline distal aortic thromboembolism: 1977-1993. J Am Anim Hosp Assoc 31 (1995) 492-522
111. Pion P.D., and Kittleson M.D. Therapy for feline aortic thromboembolism. In: Kirk R.W. (Ed). Current veterinary therapy X (1989), WB Saunders, Philadelphia 295-302
112. Hogan D.F., and Ward M.P. Effect of clopidogrel on tissue-plasminogen activator induced in vitro thrombolysis of feline whole blood thrombi. Am J Vet Res 65 6 (2004) 715-719
113. Smith SA. Warfarin treatment in small animal patients [abstract]. Proceedings of the 16th Annual ACVIM Forum, American College of Veterinary Internal Medicine, San Diego, 1998. p. 440.
114. Monnet E., and Morgan M.R. Effect of three loading doses of warfarin on the international normalized ratio for dogs. Am J Vet Res 61 1 (2000) 48-50
115. Rosanski E. Management of the hyper-coagulable patient, anticoagulant therapy. Tufts animal expo (2002) Presented at the Tufts Animal Expo. North Grafton, MA, 2002
116. Brooks M. Coagulopathies and thrombosis. In: Ettinger S., and Feldman E. (Eds). Textbook of veterinary internal medicine: diseases of the dog and cat Vol. 2 (2000), WB Saunders, Philadelphia p. 1829-41
117. Smith S.A., Lewis D.C., and Kellerman D.L. Adjustment of intermittent subcutaneous heparin therapy based on chromogenic heparin assay in 9 cats with thromboembolic disease. [abstract]. J Vet Intern Med 12 (1998) 200
118. Kellerman D.L., Lewis D.C., Bruyette D.S., et al. Determination and monitoring of a therapeutic heparin dosage in the dog. [abstract]. J Vet Intern Med 9 (1995) 187
119. Brooks M.B. Evaluation of a chromogenic assay to measure the factor Xa inhibitory activity of unfractionated heparin in canine plasma. Vet Clin Pathol 33 4 (2004) 208-214
120. Dunn M, Charland V, Thorneloe C. The use of a low molecular weight heparin in 6 dogs. Presented at the ACVIM annual meeting. Minneapolis, MN, June 2004.
121. Schaub R.G., and Rawlings C.A. Effects of long-term aspirin treatment on platelet adhesion to chronically damaged canine pulmonary arteries. Thromb Haemost 46 4 (1981) 680-683
122. Keith Jr. J.C., Rawlings C.A., and Schaub R.G. Pulmonary thromboembolism during therapy of dirofilariasis with thiacetarsamide: modification with aspirin or prednisone. Am J Vet Res 44 7 (1983) 1278-1283
123. Rawlings C.A., Keith Jr. J.C., Losonsky J.M., et al. An aspirin-prednisolone combination to modify postadulticide lung disease in heartworm-infected dogs. Am J Vet Res 45 11 (1984) 2371-2375
124. Rawlings C.A., Keith Jr. J.C., and Schaub R.G. Effect of acetylsalicylic acid on pulmonary arteriosclerosis induced by a one-year Dirofilaria immitis infection. Arteriosclerosis 5 4 (1985) 355-365
125. Boudreaux M.K., Dillon A.R., Ravis W.R., et al. Effects of treatment with aspirin or aspirin/dipyridamole combination in heartworm-negative, heartworm-infected, and embolized heartworm infected dogs. Am J Vet Res 52 12 (1991) 1992-1999
126. Tarish J.H., and Atwell R.B. The effect of prostaglandin inhibition on the development of pulmonary pathology associated with dead Dirofilaria immitis. Vet Parasitol 49 2-4 (1993) 207-217
127. 2005 guidelines for the diagnosis, prevention and management of heartworm (Dirofilaria immitis) infection in dogs. American Heartworm Society Available at: http://www.heartwormsociety.org/. Accessed September 2006.
128. Douketis J.D., Eikelboom J.W., Quinlan D.J., et al. Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes. Arch Intern Med 162 (2002) 1465-1471
129. White R.H., Romano P.S., Zhou H., et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 158 (1998) 1525-1531
130. Seagroatt V., Tan H.S., and Goldacre M. Elective total hip replacement: incidence, emergency readmission rate, and postoperative mortality. BMJ 303 (1991) 1431-1435
131. Ginsberg J.S., Gent M., Turkstra F., et al. Postthrombotic syndrome after hip or knee arthroplasty: a cross-sectional study. Arch Intern Med 160 (2000) 669-672
132. Kim Y.H., Oh S.H., and Kim J.S. Incidence and natural history of deep-vein thrombosis after total hip arthroplasty. J Bone Joint Surg Br 85 (2003) 661-665
133. Buehler K.O., D'Lima D.D., Petersilge W.J., et al. Late deep venous thrombosis and delayed weight bearing after total hip arthroplasty. Clin Orthop 361 (1999) 123-130
134. Lindahl T.L., Lundahl T.H., Nilsson L., et al. APC-resistance is a risk factor for postoperative thromboembolism in elective replacement of the hip or knee: a prospective study. Thromb Haemost 81 (1999) 18-21
135. Westrich G.H., Weksler B.B., Glueck C.J., et al. Correlation of thrombophilia and hypofibrinolysis with pulmonary embolism following total hip arthroplasty: an analysis of genetic factors. J Bone Joint Surg Am 84 (2002) 2161-2167
136. Bouthier J. The venous thrombotic risk in nonsurgical patients. Drugs 52 Suppl (1996) 16-29
137. Goldhaber S.Z., Dunn K., MacDougall R.C., et al. New onset of venous thromboembolism among hospitalized patients at Brigham and Women's Hospital is caused more often by prophylaxis failure than by withholding treatment. Chest 118 (2000) 1680-1684
138. Alikhan R., Peters F., Wilmott R., et al. Epidemiology of fatal pulmonary embolism in non-surgical patients. [abstract]. Blood 100 (2002) 276a
139. Heit J.A., Silverstein M.D., Mohr D.N., et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160 (2000) 809-815
140. Howell M.D., Geraci J.M., and Knowlton A.A. Congestive heart failure and outpatient risk of venous thromboembolism: a retrospective, case-control study. J Clin Epidemiol 54 (2001) 810-816
141. Heit J.A., O'Fallon W.M., Petterson T.M., et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 162 (2002) 1245-1248
142. Levitan N., Dowlati A., Remick S.C., et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data. Medicine 78 (1999) 285-291
143. Sallah S., Wan J.Y., and Nguyen N.P. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 87 (2002) 575-579
144. Thodiyil P.A., and Kakkar A.K. Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost 87 (2002) 1076-1077
145. Kakkar A.K., Haas S., Walsh D., et al. Prevention of perioperative venous thromboembolism: outcome after cancer and non-cancer surgery. [abstract]. Thromb Haemost 86 Suppl (2001) OC1732
146. Rajan R., Gafni A., Levine M., et al. Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: an economic evaluation. J Clin Oncol 13 (1995) 42-46
147. Attia J., Ray J.G., Cook D.J., et al. Deep vein thrombosis and its prevention in critically ill adults. Arch Intern Med 161 (2001) 1268-1279
148. Geerts W., Cook D., Selby R., et al. Venous thromboembolism and its prevention in critical care. J Crit Care 17 (2002) 95-104
149. Dorffler-Melly J., de Jonge E., de Pont A.C., et al. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet 359 (2002) 849-850
150. Liska W.D., and Poteet B.A. Pulmonary embolism associated with canine total hip replacement. Vet Surg 32 2 (2003) 178-186
151. Feldman E.C., and Nelson R.W. Canine hyperadrenocorticism (Cushing's syndrome). In: Feldman E.C., and Nelson R.W. (Eds). Canine and feline endocrinology and reproduction (2004), St Louis: WB Saunders 252-352
152. Gregory C.R., Kyles A.E., Bernsteen L., et al. Results of clinical renal transplantation in 15 dogs using triple drug immunosuppressive therapy. Vet Surg 35 2 (2006) 105-112
153. La Rue M.J., and Murtaugh R.J. Pulmonary thromboembolism in dogs: 47 cases (1986-1987). J Am Vet Med Assoc 197 10 (1990) 1368-1372
154. Johnson L.R., Lappin M.R., and Baker D.C. Pulmonary thromboembolism in 29 dogs: 1985-1995. J Vet Intern Med 13 4 (1999) 338-345
155. Schermerhorn T. Pulmonary thromboembolism in cats. J Vet Intern Med 18 4 (2004) 533-535
156. Baines E.A. Gross pulmonary thrombosis in a greyhound. J Small Anim Pract 42 9 (2001) 448-453
157. Palmer K.G. Clinical manifestations and associated disease syndromes in dogs with cranial vena cava thrombosis: 17 cases (1989-1996). J Am Vet Med Assoc 213 2 (1998) 220-224
158. Ritt M.G. Nephrotic syndrome resulting in thromboembolic disease and disseminated intravascular coagulation in a dog. J Am Anim Hosp Assoc 33 5 (1997) 385-391
159. Carter A.J. Aortic thrombosis in a dog with glomerulonephritis. J S Afr Vet Assoc 65 4 (1994) 189-192
160. Stone M.S. Lupus-type "anticoagulant" in a dog with hemolysis and thrombosis. J Vet Intern Med 8 1 (1994) 57-61
161. Green R.A. Hypercoagulable state in three dogs with nephrotic syndrome: role of acquired antithrombin III deficiency. J Am Vet Med Assoc 18 4 (2004) 533-535
162. Cook A.K., and Cowgill L.D. Clinical and pathological features of protein-losing glomerular disease in the dog: a review of 137 cases (1985-1992). J Am Anim Hosp Assoc 32 (1996) 313-322
163. Carr A.P., Panciera D.L., and Kidd L. Prognostic factors for mortality and thromboembolism in canine immune-mediated hemolytic anemia: a retrospective study of 72 dogs. J Vet Intern Med 16 5 (2002) 504-509
164. Tilley L.P., Liu S.K., Gilbertson S.R., et al. Primary myocardial disease in the cat. A model for human cardiomyopathy. Am J Pathol 86 (1977) 493-522
165. Grauer G.F. CVT update: canine glomerulonephritis. In: Bonagura J.D. (Ed). Kirk's current veterinary therapy XIII (2000), WB Saunders Co, Philadelphia 851-853
166. Abdullah R. Hemostatic abnormalities in nephrotic syndrome. Vet Clin North Am Small Anim Pract 18 1 (1988) 105-113
167. Rasedee A., and Feldman B.F. Nephrotic syndrome: a platelet hyperaggregability state. Vet Res Commun 9 (1985) 199-211
168. Littman M.P., Dambach D.M., Vaden S.L., et al. Familial protein-enteropathy and protein-losing nephropathy in soft coated wheaten terriers: 222 cases (1983-1997). J Vet Intern Med 14 (2000) 68-80
169. Otto C.M., Reiser T.M., Brooks M.B., et al. Evidence of hypercoagulability in dogs with parvoviral enteritis. J Am Vet Med Assoc 217 10 (2000) 1500-1504
170. Nichols R. Complications and concurrent disease associated with canine hyperadrenocorticism. Vet Clin North Am Small Anim Pract 27 2 (1997) 309-319
171. Scott-Moncreiff J.C., Treadwell N.G., McCullough S.M., et al. Hemostatic abnormalities in dogs with primary immune-mediated anemia. J Am Anim Hosp Assoc 37 (2001) 220-227
172. Klein M.K., Dow S.W., and Rosychuck R.A.W. Pulmonary thromboembolism associated with immune-mediated hemolytic anemia in dogs: ten cases (1982-1987). J Am Vet Med Assoc 195 (1989) 246-250
173. McManus P.M., and Craig L.E. Correlation between leukocytosis and necropsy findings in dogs with immune-mediated hemolytic anemia: 34 cases (1994-1999). J Am Vet Med Assoc 218 (2001) 1308-1313
174. Weinkle T.K., Center S.A., Randolf J.F., et al. Evaluation of prognostic factors, survival rates, and treatment protocols for immune-mediated hemolytic anemia in dogs: 151 cases (1993-2002). J Am Vet Med Assoc 226 11 (2005) 1869-1880
175. Slappendel R.J. Disseminated intravascular coagulation. Vet Clin North Am Small Anim Pract 18 1 (1988) 169-184
176. Owen C.A., and Bowie E.J.W. Effect of heparin on chronically induced intravascular coagulation in dogs. Am J Physiol (1975) 229-249
177. Mant M.J., and King E.G. Severe, acute disseminated intravascular coagulation. A reappraisal of its pathophysiology, clinical significance and therapy, based on 47 patients. Am J Med 67 4 (1979) 557-563
178. Mischke R., Fehr M., and Nolte I. Efficacy of low molecular weight heparin in a canine model of thromboplastin-induced disseminated intravascular coagulation. Res Vet Sci 79 1 (2005) 69-76
179. O'Keefe D.A., and Couto G. Coagulation abnormalities associated with neoplasia. Vet Clin North Am Small Anim Pract 18 1 (1988) 157-167